ClinicalTrials.gg
Active, not recruitingNCT06263478Updated Oct 5, 2026Results posted

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease

A Phase 3 interventional study of INCA034176 in Chronic Graft-versus-host-disease, sponsored by Incyte Biosciences Japan GK. Active, not recruiting at 16 sites in Japan. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Incyte Biosciences Japan GK (part of Incyte Corporation) · Phase 3, Interventional, and Treatment

Updated Oct 5, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
21
Allocation
Not applicable
Ages
6 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing axatilimab in Bronchiolitis Obliterans Syndrome — 5 open to participants now, 9 under way, 3 of them phase 3. axatilimab · Bronchiolitis Obliterans Syndrome.

Enrollment
9th of 10
21 · median 50
Started
2024
with 1 other
Phase 3
3 of 10
1 open now
Registered
3rd of 10
by date
Lead sponsor
1 of 10
Incyte Biosciences Japan GK

Among the 10 studies testing axatilimab in Bronchiolitis Obliterans Syndrome, this one is the 9th largest by enrollment, is one of 2 that started in 2024, is one of 3 in phase 3, and was the 3rd registered.

Bronchiolitis Obliterans Syndrome

714 studies on the registry are indexed under Bronchiolitis Obliterans Syndrome; 128 are open to participants now.

Browse Bronchiolitis Obliterans Syndrome studies →

Open to participants now

5 of the 10 studies testing axatilimab in Bronchiolitis Obliterans Syndrome are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About axatilimab

axatilimab: first FDA approval 2024 (NIKTIMVO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 100 Bronchiolitis Obliterans Syndrome studies recruiting now, 45 (45%) set no upper age limit and 45 (45%) stop at 75 or younger; 25 take children under 18; 12 take healthy volunteers.

This study: 6 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing axatilimab in Bronchiolitis Obliterans Syndrome, or all of them as a file.
02

Study summary

This study will be conducted to determine the clinical efficacy of axatilimab in Japanese participants with chronic graft-versus-host disease (cGVHD).

03

Conditions studied

  • Chronic Graft-versus-host-disease

Keywords

  • cGVHD
04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 6 years of age at the time of signing the ICF.
  • Ability to comprehend and willingness to sign a written ICF for the study.

    • For participants 6 to 17 years old, a parent/guardian must provide consent for pediatric participants; when applicable, pediatric participants should also sign an assent form.
  • Japanese participants who are recipients with active, , or recurrent cGVHD requiring systemic immune suppression despite at least 2 lines of prior systemic therapy.

    • Active cGVHD is defined as the presence of signs and symptoms of cGVHD per the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD.
    • Refractory disease is defined as meeting any of the following criteria:

      • The development of 1 or more new sites of disease while being treated for cGVHD.
      • Progression of existing sites of disease despite at least 1 month of standard or therapy for cGVHD.
      • Participants who did not achieve a response within 3 months on prior therapy for cGVHD and for whom the treating physician believes a new systemic therapy is required.
    • Recurrent cGVHD is defined as active, symptomatic disease (after an initial response to prior therapy) based on the NIH 2014 consensus criteria by organ-specific or global assessment or for which the physician believes a new is required.
  • Participants may have persistent, active aGVHD and cGVHD manifestations (overlap syndrome), as defined by the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD.
  • performance score of ≥ 60 (if aged 16 years or older); Lansky performance score of ≥ 60 (if aged younger than 16 years).
  • Adequate organ and bone marrow functions evaluated during the 14 days prior to the start of study treatment.
  • ≥ 30 mL/min based on the Cockcroft-Gault formula in adult participants and Schwartz formula in pediatric participants.
  • Concomitant use of a systemic is allowed but not required. Topical and inhaled corticosteroid agents are allowed. If a participant is taking a corticosteroid, it must be a stable dose for at least 2 weeks prior to the start of study treatment.
  • Concomitant use of protocol-defined is allowed but not required.
  • Willingness to avoid pregnancy or fathering children based on protocol-defined criteria.

Exclusion criteria

Exclusion Criteria:

  • Has aGVHD without manifestations of cGVHD.
  • Any evidence (histologic, cytogenetic, molecular, hematologic, or mixed) of relapse of the underlying cancer or post-transplant lymphoproliferative disease at the time of screening.
  • History of acute or chronic pancreatitis.
  • History of myositis.
  • History or other evidence of severe illness, uncontrolled infection, allergy to , or any other conditions that would make the participant, in the opinion of the investigator, unsuitable for the study.
  • Has acquired immunodeficiency syndrome.
  • History of latent or active TB based on protocol-defined criteria.
  • Active or infection that requires treatment, or at risk for HBV reactivation (ie, positive HBsAg).
  • Pregnant or breastfeeding.
  • Previous exposure to CSF-1R targeted therapies.
  • Use of any agent other than , or the for the treatment of cGVHD within 2 weeks or 5 half-lives, whichever is shorter, prior to the start of study treatment.
  • Has received an treatment within 28 days prior to the start of study treatment.
  • Currently participating in any other interventional study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Axatilimab Dose

    Axatilimab at the protocol-defined dose.

    Drug: INCA034176

Interventions

  • IV infusion

    Also known as: Axatilimab

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR) in the First 6 Treatment Cycles, as Defined by the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD

    ORR was defined as the percentage of participants with a physician-assessed complete response (CR) or a physician-assessed partial response (PR), evaluated as defined by the 2014 National Institutes of Health (NIH) Consensus Development Project on Criteria for Clinical Trials in chronic graft-versus-host disease (cGVHD). A participant was considered an objective responder if they had an overall response of CR or PR at any timepoint up to the beginning of Cycle 7. CR was defined as the resolution of all manifestations in each organ or site, and PR was defined as improvement in at least 1 organ or site without progression in any other organ or site.

    Time frame: up to the end of Cycle 6 (up to 168 days)

Secondary outcomes

  1. Percentage of Participants With a ≥7-point Improvement in Modified Lee Symptom Scale (mLSS) Score

    The mLSS is a 28-item instrument comprising 7 subscales, designed to assess the impact of cGVHD on a participant's symptoms. Participants were asked to indicate the degree of "bother" during the past 7 days due to symptoms in 7 domains (skin, eyes and mouth, breathing, eating and digestion, muscles and joints, energy, emotional distress) potentially affected by cGVHD. A mLSS responder is defined as a participant who achieved at least a 7-point improvement from baseline in the normalized mLSS score. This score is on a 0-100 scale, calculated as the average of the subscale scores.

    Time frame: before Cycle 7 Day 1 (up to 168 days); during study (up to 12.8 months)

  2. ORR, as Defined by the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD

    ORR was defined as the percentage of participants with a physician-assessed CR or a physician-assessed PR, evaluated as defined by the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD. A participant was considered an objective responder if they had an overall response of CR or PR at any post-baseline visit. CR was defined as the resolution of all manifestations in each organ or site, and PR was defined as improvement in at least 1 organ or site without progression in any other organ or site.

    Time frame: up to 12.8 months

  3. Duration of Response (DOR) in Participants With a Response in the First 6 Treatment Cycles

    Duration of response was defined as the time from the first response of either CR or PR until progression of cGVHD, start of another anti-GVHD treatment, or death from any cause, whichever was earlier. CR was defined as the resolution of all manifestations in each organ or site, and PR was defined as improvement in at least 1 organ or site without progression in any other organ or site. DOR was assessed for participants whose first CR or PR occurred during the first 6 treatment cycles. A response was followed until the response ended, regardless of whether the response ended during the first 6 treatment cycles or after Cycle 6.

    Time frame: up to 13.8 months (maximum duration of treatment [12.8 months] plus 30 days)

  4. Organ-specific Response Rate

    Organ-specific response rate was defined as the percentage of participants with a CR or PR for the 9 individual organs based on the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD (skin, eyes, mouth, esophagus, upper gastrointestinal (GI) tract, lower GI, liver, lungs, and joints and fascia) in participants with each corresponding organ involvement at baseline.

    Time frame: up to 12.8 months

  5. Percent Reduction in Average Daily Dose (or Equivalent) of Corticosteroids in the First 6 Treatment Cycles

    Participants may have been taking a corticosteroid upon study entry. At the discretion of the investigator, the corticosteroid dose may have been tapered after the first 4 weeks of study drug administration for participants who achieved either a PR or CR. Percent reduction was calculated as the (\[difference between the baseline value and the post-baseline value\]/divided by the baseline value) x 100.

    Time frame: up to the end of Cycle 6 (up to 168 days)

  6. Percentage of Participants Who Discontinued Corticosteroid Use After Study Entry in the First 6 Treatment Cycles

    Participants may have been taking a corticosteroid upon study entry. At the discretion of the investigator, the corticosteroid dose may have been tapered after the first 4 weeks of study drug administration for participants who achieved either a PR or CR.

    Time frame: up to the end of Cycle 6 (up to 168 days)

  7. Number of Participants With Any Treatment-emergent Adverse Event (TEAE)

    An adverse event was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. For the purposes of analysis, all AEs were considered to be TEAEs unless the AE could unequivocally be defined as not treatment emergent.

    Time frame: up to 13.8 months

  8. Number of Participants With Any ≥Grade 3 TEAE

    An adverse event was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. For the purposes of analysis, all AEs were considered to be TEAEs unless the AE could unequivocally be defined as not treatment emergent. The severity of AEs was assessed using Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0) Grades 1 through 5. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.

    Time frame: up to 13.8 months

  9. Change From Baseline in Karnofsky/Lansky Performance Status

    The Karnofsky/Lansky performance status allows participants to be classified as to their functional impairment on a scale from 0 to 100. The lower the score, the worse the survival for most serious illnesses. The score can be used to compare the effectiveness of different therapies and to assess the prognosis in individual participants. The Karnofsky scale is designed for participants aged 16 years and older, and the Lansky scale is designed for participants younger than 16 years. Change from baseline was calculated as the post-baseline value minus the baseline value.

    Time frame: up to 13.8 months

  10. Percentage of Participants Positive for Anti-drug Antibodies (ADAs)

    Antibodies to axatilimab were evaluated in plasma samples collected from all participants.

    Time frame: up to 12.8 months

  11. INCA034176 Concentration

    Plasma samples were collected for pharmacokinetic (PK) analysis.

    Time frame: up to 12.8 months

07

Results

Posted Oct 5, 2026

Participant flow

Participant flow — Overall Study
MilestoneAxatilimab 0.3 mg/kg Q2W IV
Started21
Completed0
Not completed21
Withdrew: Ongoing19
Withdrew: Lung transplantation1
Withdrew: Physician decision1

Outcome measures

PrimaryOverall Response Rate (ORR) in the First 6 Treatment Cycles, as Defined by the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD

ORR was defined as the percentage of participants with a physician-assessed complete response (CR) or a physician-assessed partial response (PR), evaluated as defined by the 2014 National Institutes of Health (NIH) Consensus Development Project on Criteria for Clinical Trials in chronic graft-versus-host disease (cGVHD). A participant was considered an objective responder if they had an overall response of CR or PR at any timepoint up to the beginning of Cycle 7. CR was defined as the resolution of all manifestations in each organ or site, and PR was defined as improvement in at least 1 organ or site without progression in any other organ or site.

Time frame:
up to the end of Cycle 6 (up to 168 days)
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) in the First 6 Treatment Cycles, as Defined by the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD
percentage of participantsAxatilimab 0.3 mg/kg IV Q2W
Overall Response Rate (ORR) in the First 6 Treatment Cycles, as Defined by the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD71.4 (47.8 to 88.7)
SecondaryPercentage of Participants With a ≥7-point Improvement in Modified Lee Symptom Scale (mLSS) Score

The mLSS is a 28-item instrument comprising 7 subscales, designed to assess the impact of cGVHD on a participant's symptoms. Participants were asked to indicate the degree of "bother" during the past 7 days due to symptoms in 7 domains (skin, eyes and mouth, breathing, eating and digestion, muscles and joints, energy, emotional distress) potentially affected by cGVHD. A mLSS responder is defined as a participant who achieved at least a 7-point improvement from baseline in the normalized mLSS score. This score is on a 0-100 scale, calculated as the average of the subscale scores.

Time frame:
before Cycle 7 Day 1 (up to 168 days); during study (up to 12.8 months)
Reported as:
Number · percentage of participants
Percentage of Participants With a ≥7-point Improvement in Modified Lee Symptom Scale (mLSS) Score
percentage of participantsAxatilimab 0.3 mg/kg IV Q2W
mLSS reduction ≥7 points on or before Cycle 7 Day 145.0 (23.1 to 68.5)
mLSS reduction ≥7 points on study50.0 (27.2 to 72.8)
SecondaryORR, as Defined by the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD

ORR was defined as the percentage of participants with a physician-assessed CR or a physician-assessed PR, evaluated as defined by the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD. A participant was considered an objective responder if they had an overall response of CR or PR at any post-baseline visit. CR was defined as the resolution of all manifestations in each organ or site, and PR was defined as improvement in at least 1 organ or site without progression in any other organ or site.

Time frame:
up to 12.8 months
Reported as:
Number · percentage of participants
ORR, as Defined by the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD
percentage of participantsAxatilimab 0.3 mg/kg IV Q2W
ORR, as Defined by the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD76.2 (52.8 to 91.8)
SecondaryDuration of Response (DOR) in Participants With a Response in the First 6 Treatment Cycles

Duration of response was defined as the time from the first response of either CR or PR until progression of cGVHD, start of another anti-GVHD treatment, or death from any cause, whichever was earlier. CR was defined as the resolution of all manifestations in each organ or site, and PR was defined as improvement in at least 1 organ or site without progression in any other organ or site. DOR was assessed for participants whose first CR or PR occurred during the first 6 treatment cycles. A response was followed until the response ended, regardless of whether the response ended during the first 6 treatment cycles or after Cycle 6.

Time frame:
up to 13.8 months (maximum duration of treatment [12.8 months] plus 30 days)
Reported as:
Median · months
Duration of Response (DOR) in Participants With a Response in the First 6 Treatment Cycles
monthsAxatilimab 0.3 mg/kg IV Q2W
Duration of Response (DOR) in Participants With a Response in the First 6 Treatment CyclesNA (NA to NA)
SecondaryOrgan-specific Response Rate

Organ-specific response rate was defined as the percentage of participants with a CR or PR for the 9 individual organs based on the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD (skin, eyes, mouth, esophagus, upper gastrointestinal (GI) tract, lower GI, liver, lungs, and joints and fascia) in participants with each corresponding organ involvement at baseline.

Time frame:
up to 12.8 months
Reported as:
Number · percentage of participants
Organ-specific Response Rate
percentage of participantsAxatilimab 0.3 mg/kg IV Q2W
Skin30.8 (9.1 to 61.4)
Eyes0.0 (0.0 to 23.2)
Mouth61.5 (31.6 to 86.1)
Lower GI tract50.0 (1.3 to 98.7)
Liver100.0 (2.5 to 100.0)
Lungs18.2 (2.3 to 51.8)
Joints and fascia90.0 (55.5 to 99.7)
SecondaryPercent Reduction in Average Daily Dose (or Equivalent) of Corticosteroids in the First 6 Treatment Cycles

Participants may have been taking a corticosteroid upon study entry. At the discretion of the investigator, the corticosteroid dose may have been tapered after the first 4 weeks of study drug administration for participants who achieved either a PR or CR. Percent reduction was calculated as the (\[difference between the baseline value and the post-baseline value\]/divided by the baseline value) x 100.

Time frame:
up to the end of Cycle 6 (up to 168 days)
Reported as:
Mean · percent reduction
Percent Reduction in Average Daily Dose (or Equivalent) of Corticosteroids in the First 6 Treatment Cycles
percent reductionAxatilimab 0.3 mg/kg IV Q2W
Day 1 to ≤Day 280.00 ± 0.000
Day 29 to ≤Day 560.00 ± 0.000
Day 57 to ≤Day 840.98 ± 2.346
Day 85 to ≤Day 1124.02 ± 6.589
Day 113 to ≤Day 14011.31 ± 16.097
Day 141 to ≤Day 16817.47 ± 21.940
SecondaryPercentage of Participants Who Discontinued Corticosteroid Use After Study Entry in the First 6 Treatment Cycles

Participants may have been taking a corticosteroid upon study entry. At the discretion of the investigator, the corticosteroid dose may have been tapered after the first 4 weeks of study drug administration for participants who achieved either a PR or CR.

Time frame:
up to the end of Cycle 6 (up to 168 days)
Reported as:
Number · percentage of participants
Percentage of Participants Who Discontinued Corticosteroid Use After Study Entry in the First 6 Treatment Cycles
percentage of participantsAxatilimab 0.3 mg/kg IV Q2W
Percentage of Participants Who Discontinued Corticosteroid Use After Study Entry in the First 6 Treatment Cycles0.0
SecondaryNumber of Participants With Any Treatment-emergent Adverse Event (TEAE)

An adverse event was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. For the purposes of analysis, all AEs were considered to be TEAEs unless the AE could unequivocally be defined as not treatment emergent.

Time frame:
up to 13.8 months
Reported as:
Count of participants · Participants
Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
ParticipantsAxatilimab 0.3 mg/kg IV Q2W
Number of Participants With Any Treatment-emergent Adverse Event (TEAE)20
SecondaryNumber of Participants With Any ≥Grade 3 TEAE

An adverse event was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. For the purposes of analysis, all AEs were considered to be TEAEs unless the AE could unequivocally be defined as not treatment emergent. The severity of AEs was assessed using Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0) Grades 1 through 5. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.

Time frame:
up to 13.8 months
Reported as:
Count of participants · Participants
Number of Participants With Any ≥Grade 3 TEAE
ParticipantsAxatilimab 0.3 mg/kg IV Q2W
Number of Participants With Any ≥Grade 3 TEAE8
SecondaryChange From Baseline in Karnofsky/Lansky Performance Status

The Karnofsky/Lansky performance status allows participants to be classified as to their functional impairment on a scale from 0 to 100. The lower the score, the worse the survival for most serious illnesses. The score can be used to compare the effectiveness of different therapies and to assess the prognosis in individual participants. The Karnofsky scale is designed for participants aged 16 years and older, and the Lansky scale is designed for participants younger than 16 years. Change from baseline was calculated as the post-baseline value minus the baseline value.

Time frame:
up to 13.8 months
Reported as:
Mean · scores on a scale
Change From Baseline in Karnofsky/Lansky Performance Status
scores on a scaleAxatilimab 0.3 mg/kg IV Q2W
Baseline, Karnofsky performance status score (KPSS)87.8 ± 4.28
Baseline, Lansky performance status score (LPSS)80.0 ± 10.00
Change from baseline in KPSS at Cycle 2 Day 10.6 ± 4.16
Change from baseline in LPSS at Cycle 2 Day 13.3 ± 5.77
Change from baseline in KPSS at Cycle 3 Day 1-0.6 ± 4.29
Change from baseline in LPSS at Cycle 3 Day 10.0 ± 0.00
Change from baseline in KPSS at Cycle 4 Day 10.0 ± 5.00
Change from baseline in LPSS at Cycle 4 Day 10.0 ± 10.00
Change from baseline in KPSS at Cycle 5 Day 1-0.6 ± 5.56
Change from baseline in LPSS at Cycle 5 Day 1-5.0 ± 7.07
Change from baseline in KPSS at Cycle 6 Day 1-0.6 ± 5.56
Change from baseline in LPSS at Cycle 6 Day 1-5.0 ± 7.07
Change from baseline in KPSS at Cycle 7 Day 1-1.2 ± 6.97
Change from baseline in LPSS at Cycle 7 Day 1-5.0 ± 7.07
Change from baseline in KPSS at Cycle 8 Day 10.0 ± 5.55
Change from baseline in LPSS at Cycle 8 Day 1-5.0 ± 7.07
Change from baseline in KPSS at Cycle 9 Day 10.0 ± 5.55
Change from baseline in LPSS at Cycle 9 Day 10.0 ± NA
Change from baseline in KPSS at Cycle 10 Day 11.5 ± 5.55
Change from baseline in LPSS at Cycle 10 Day 10.0 ± NA
Change from baseline in KPSS at Cycle 11 Day 11.0 ± 5.68
Change from baseline in LPSS at Cycle 11 Day 10.0 ± NA
Change from baseline in KPSS at Cycle 12 Day 10.0 ± 7.07
Change from baseline in LPSS at Cycle 12 Day 10.0 ± NA
Change from baseline in KPSS at Cycle 13 Day 10.0 ± 8.16
Change from baseline in KPSS at Cycle 14 Day 1-10.0 ± NA
Change from baseline in KPSS at end of treatment-10.0 ± NA
Change from baseline in LPSS at end of treatment10.0 ± NA
SecondaryPercentage of Participants Positive for Anti-drug Antibodies (ADAs)

Antibodies to axatilimab were evaluated in plasma samples collected from all participants.

Time frame:
up to 12.8 months
Reported as:
Number · percentage of participants
Percentage of Participants Positive for Anti-drug Antibodies (ADAs)
percentage of participantsAxatilimab 0.3 mg/kg IV Q2W
Percentage of Participants Positive for Anti-drug Antibodies (ADAs)23.8
SecondaryINCA034176 Concentration

Plasma samples were collected for pharmacokinetic (PK) analysis.

Time frame:
up to 12.8 months
Reported as:
Median · nanograms per milliliter (ng/mL)
INCA034176 Concentration
nanograms per milliliter (ng/mL)Axatilimab 0.3 mg/kg IV Q2W
INCA034176 ConcentrationNA (NA to 13314)

Adverse events

Collected over up to 13.8 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Axatilimab 0.3 mg/kg Q2W IV0/21 (0%)7/21 (33.3%)19/21 (90.5%)
Most frequent serious events
Most frequent serious events
EventAxatilimab 0.3 mg/kg Q2W IV
AppendicitisInfections and infestations1/21
AsthmaRespiratory, thoracic and mediastinal disorders1/21
COVID-19Infections and infestations1/21
Cystitis viralInfections and infestations1/21
DehydrationMetabolism and nutrition disorders1/21
Large intestine polypGastrointestinal disorders1/21
Pneumonia influenzalInfections and infestations1/21
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/21
Spinal stenosisMusculoskeletal and connective tissue disorders1/21
Urinary tract infectionInfections and infestations1/21
Most frequent other events
Showing 10 of 24
Most frequent other events
EventAxatilimab 0.3 mg/kg Q2W IV
NasopharyngitisInfections and infestations7/21
InfluenzaInfections and infestations5/21
DiarrhoeaGastrointestinal disorders4/21
HeadacheNervous system disorders4/21
Oedema peripheralGeneral disorders4/21
PruritusSkin and subcutaneous tissue disorders4/21
BronchitisInfections and infestations3/21
ConstipationGastrointestinal disorders3/21
Alanine aminotransferase increasedInvestigations2/21
AnaemiaBlood and lymphatic system disorders2/21

Baseline characteristics

Age, Continuous
Age, Continuous(years)Axatilimab 0.3 mg/kg Q2W IV
Mean41.9 ± 19.64
Sex: Female, Male
Sex: Female, Male(Participants)Axatilimab 0.3 mg/kg Q2W IV
Female8
Male13
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Axatilimab 0.3 mg/kg Q2W IV
Hispanic or Latino0
Not Hispanic or Latino21
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Axatilimab 0.3 mg/kg Q2W IV
Asian21
08

Study locations

16 sites
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.

Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.

Data sharing details ↗ · www.incyte.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2024 to primary completion in Aug 2025, 12 months.

Results were first posted in Oct 2026, 1 year 1 month after primary completion.

Of 30 phase 3 interventional studies under Bronchiolitis Obliterans Syndrome, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 62. This study's 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2024
First posted
Feb 16, 2024
StartActual
Jul 30, 2024
Primary completionActual
Aug 6, 2025
CompletionEst.
Mar 30, 2027
Results first posted
Oct 5, 2026
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 5, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Overall Response Rate in the First 6 CyclesNow Overall Response Rate (ORR) in the First 6 Treatment Cycles, as Defined by the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHDTime frame: Up to Cycle 7 (Day 169) → up to the end of Cycle 6 (up to 168 days)
Oct 5, 2026
Documents
Secondary outcomes
5 edited, 1 time frame changed, 5 added, 4 removed, 1 description edited
What changed in the outcomes
  • EditedProportionPercentage of participants withParticipants With a ≥ 7-point improvementImprovement in modifiedModified Lee symptom scaleSymptom Scale (mLSS) scoreScoreTime frame: Up to 2 years → before Cycle 7 Day 1 (up to 168 days); during study (up to 12.8 months)
  • EditedPercent reductionReduction in average daily doseAverage Daily Dose (or equivalentEquivalent) of corticosteroidsCorticosteroids in the First 6 Treatment CyclesTime frame: Up to 2 years → up to the end of Cycle 6 (up to 168 days)
  • EditedNumber of participants withParticipants With Any Treatment-emergent Adverse EventsEvent (TEAEsTEAE)Time frame: Up to 2 years and 30 days → up to 13.8 months
  • EditedChange from baselineFrom Baseline in Karnofsky/Lansky performance statusPerformance StatusTime frame: Up to 2 years and 30 days → up to 13.8 months
  • EditedNumberPercentage of Participants withPositive for Anti-Drug Antibodydrug Antibodies (ADAADAs)Time frame: Up to 2 years and 30 days → up to 12.8 months
  • AddedORR, as Defined by the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHDTime frame: up to 12.8 months
  • AddedDuration of Response (DOR) in Participants With a Response in the First 6 Treatment CyclesTime frame: up to 13.8 months (maximum duration of treatment [12.8 months] plus 30 days)
  • AddedPercentage of Participants Who Discontinued Corticosteroid Use After Study Entry in the First 6 Treatment CyclesTime frame: up to the end of Cycle 6 (up to 168 days)
  • AddedNumber of Participants With Any ≥Grade 3 TEAETime frame: up to 13.8 months
  • AddedINCA034176 ConcentrationTime frame: up to 12.8 months
  • RemovedOverall Response RateTime frame: Up to 2 years
  • RemovedDuration of ResponseTime frame: Up to 2 years
  • RemovedProportion of participants who discontinue corticosteroid useTime frame: Up to 2 years
  • RemovedAxatilimab pharmacokinetic (PK) in PlasmaTime frame: Up to 2 years and 30 days
  • Time frameOrgan-specific Response RateUp to 2 years → up to 12.8 months
  • DescriptionOrgan-specific Response Rate: how it is measured was reworded
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Overall Response Rate in the First 6 CyclesNow Overall Response Rate (ORR) in the First 6 Treatment Cycles, as Defined by the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHDTime frame: Up to Cycle 7 (Day 169) → up to the end of Cycle 6 (up to 168 days)
    Secondary outcomes 5 edited, 1 time frame changed, 5 added, 4 removed, 1 description edited
    What changed in the outcomes
    • EditedProportionPercentage of participants withParticipants With a ≥ 7-point improvementImprovement in modifiedModified Lee symptom scaleSymptom Scale (mLSS) scoreScoreTime frame: Up to 2 years → before Cycle 7 Day 1 (up to 168 days); during study (up to 12.8 months)
    • EditedPercent reductionReduction in average daily doseAverage Daily Dose (or equivalentEquivalent) of corticosteroidsCorticosteroids in the First 6 Treatment CyclesTime frame: Up to 2 years → up to the end of Cycle 6 (up to 168 days)
    • EditedNumber of participants withParticipants With Any Treatment-emergent Adverse EventsEvent (TEAEsTEAE)Time frame: Up to 2 years and 30 days → up to 13.8 months
    • EditedChange from baselineFrom Baseline in Karnofsky/Lansky performance statusPerformance StatusTime frame: Up to 2 years and 30 days → up to 13.8 months
    • EditedNumberPercentage of Participants withPositive for Anti-Drug Antibodydrug Antibodies (ADAADAs)Time frame: Up to 2 years and 30 days → up to 12.8 months
    • AddedORR, as Defined by the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHDTime frame: up to 12.8 months
    • AddedDuration of Response (DOR) in Participants With a Response in the First 6 Treatment CyclesTime frame: up to 13.8 months (maximum duration of treatment [12.8 months] plus 30 days)
    • AddedPercentage of Participants Who Discontinued Corticosteroid Use After Study Entry in the First 6 Treatment CyclesTime frame: up to the end of Cycle 6 (up to 168 days)
    • AddedNumber of Participants With Any ≥Grade 3 TEAETime frame: up to 13.8 months
    • AddedINCA034176 ConcentrationTime frame: up to 12.8 months
    • RemovedOverall Response RateTime frame: Up to 2 years
    • RemovedDuration of ResponseTime frame: Up to 2 years
    • RemovedProportion of participants who discontinue corticosteroid useTime frame: Up to 2 years
    • RemovedAxatilimab pharmacokinetic (PK) in PlasmaTime frame: Up to 2 years and 30 days
    • Time frameOrgan-specific Response RateUp to 2 years → up to 12.8 months
    • DescriptionOrgan-specific Response Rate: how it is measured was reworded
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06263478
Responsible party
Sponsor
First posted
Feb 16, 2024
Start date
Jul 30, 2024
Primary completion
Aug 6, 2025
Completion
Mar 30, 2027 (estimated)
Results posted
Oct 5, 2026
Last update
Oct 5, 2026

Study contacts

Incyte Medical Monitor
study director · Incyte Corporation

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Axatilimab

Start the discussion